PortalPublikationenEffect of empirical treatment with moxifloxacin and meropene...

Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.

Standard

Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. / Brunkhorst, Frank M; Oppert, Michael; Marx, Gernot; Bloos, Frank; Ludewig, Katrin; Putensen, Christian; Nierhaus, Axel; Jaschinski, Ulrich; Meier-Hellmann, Andreas; Weyland, Andreas; Gründling, Matthias; Moerer, Onnen; Riessen, Reimer; Seibel, Armin; Ragaller, Maximilian; Büchler, Markus W; John, Stefan; Bach, Friedhelm; Spies, Claudia; Reill, Lorenz; Fritz, Harald; Kiehntopf, Michael; Kuhnt, Evelyn; Bogatsch, Holger; Engel, Christoph; Loeffler, Markus; Kollef, Marin H; Reinhart, Konrad; Welte, Tobias; Sepsis, German Study Group Competence Network.

in: JAMA-J AM MED ASSOC, Jahrgang 307, Nr. 22, 22, 2012, S. 2390-2399.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Brunkhorst, FM, Oppert, M, Marx, G, Bloos, F, Ludewig, K, Putensen, C, Nierhaus, A, Jaschinski, U, Meier-Hellmann, A, Weyland, A, Gründling, M, Moerer, O, Riessen, R, Seibel, A, Ragaller, M, Büchler, MW, John, S, Bach, F, Spies, C, Reill, L, Fritz, H, Kiehntopf, M, Kuhnt, E, Bogatsch, H, Engel, C, Loeffler, M, Kollef, MH, Reinhart, K, Welte, T & Sepsis, GSGCN 2012, 'Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.', JAMA-J AM MED ASSOC, Jg. 307, Nr. 22, 22, S. 2390-2399. <http://www.ncbi.nlm.nih.gov/pubmed/22692171?dopt=Citation>

APA

Brunkhorst, F. M., Oppert, M., Marx, G., Bloos, F., Ludewig, K., Putensen, C., Nierhaus, A., Jaschinski, U., Meier-Hellmann, A., Weyland, A., Gründling, M., Moerer, O., Riessen, R., Seibel, A., Ragaller, M., Büchler, M. W., John, S., Bach, F., Spies, C., ... Sepsis, G. S. G. C. N. (2012). Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA-J AM MED ASSOC, 307(22), 2390-2399. [22]. http://www.ncbi.nlm.nih.gov/pubmed/22692171?dopt=Citation

Vancouver

Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA-J AM MED ASSOC. 2012;307(22):2390-2399. 22.

Bibtex

@article{5bd42400c22e4035bcd0438a64bc5f87,
title = "Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.",
abstract = "Early appropriate antimicrobial therapy leads to lower mortality rates associated with severe sepsis. The role of empirical combination therapy comprising at least 2 antibiotics of different mechanisms remains controversial.",
keywords = "Humans, Male, Aged, Female, Middle Aged, Treatment Outcome, Survival Analysis, Drug Therapy, Combination, Anti-Bacterial Agents/*therapeutic use, Aza Compounds/*therapeutic use, Multiple Organ Failure/*etiology/*prevention & control, Quinolines/*therapeutic use, Sepsis/*complications/*drug therapy, Shock, Septic/complications/drug therapy, Thienamycins/*therapeutic use, Humans, Male, Aged, Female, Middle Aged, Treatment Outcome, Survival Analysis, Drug Therapy, Combination, Anti-Bacterial Agents/*therapeutic use, Aza Compounds/*therapeutic use, Multiple Organ Failure/*etiology/*prevention & control, Quinolines/*therapeutic use, Sepsis/*complications/*drug therapy, Shock, Septic/complications/drug therapy, Thienamycins/*therapeutic use",
author = "Brunkhorst, {Frank M} and Michael Oppert and Gernot Marx and Frank Bloos and Katrin Ludewig and Christian Putensen and Axel Nierhaus and Ulrich Jaschinski and Andreas Meier-Hellmann and Andreas Weyland and Matthias Gr{\"u}ndling and Onnen Moerer and Reimer Riessen and Armin Seibel and Maximilian Ragaller and B{\"u}chler, {Markus W} and Stefan John and Friedhelm Bach and Claudia Spies and Lorenz Reill and Harald Fritz and Michael Kiehntopf and Evelyn Kuhnt and Holger Bogatsch and Christoph Engel and Markus Loeffler and Kollef, {Marin H} and Konrad Reinhart and Tobias Welte and Sepsis, {German Study Group Competence Network}",
year = "2012",
language = "English",
volume = "307",
pages = "2390--2399",
journal = "JAMA-J AM MED ASSOC",
issn = "0098-7484",
publisher = "American Medical Association",
number = "22",

}

RIS

TY - JOUR

T1 - Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.

AU - Brunkhorst, Frank M

AU - Oppert, Michael

AU - Marx, Gernot

AU - Bloos, Frank

AU - Ludewig, Katrin

AU - Putensen, Christian

AU - Nierhaus, Axel

AU - Jaschinski, Ulrich

AU - Meier-Hellmann, Andreas

AU - Weyland, Andreas

AU - Gründling, Matthias

AU - Moerer, Onnen

AU - Riessen, Reimer

AU - Seibel, Armin

AU - Ragaller, Maximilian

AU - Büchler, Markus W

AU - John, Stefan

AU - Bach, Friedhelm

AU - Spies, Claudia

AU - Reill, Lorenz

AU - Fritz, Harald

AU - Kiehntopf, Michael

AU - Kuhnt, Evelyn

AU - Bogatsch, Holger

AU - Engel, Christoph

AU - Loeffler, Markus

AU - Kollef, Marin H

AU - Reinhart, Konrad

AU - Welte, Tobias

AU - Sepsis, German Study Group Competence Network

PY - 2012

Y1 - 2012

N2 - Early appropriate antimicrobial therapy leads to lower mortality rates associated with severe sepsis. The role of empirical combination therapy comprising at least 2 antibiotics of different mechanisms remains controversial.

AB - Early appropriate antimicrobial therapy leads to lower mortality rates associated with severe sepsis. The role of empirical combination therapy comprising at least 2 antibiotics of different mechanisms remains controversial.

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Survival Analysis

KW - Drug Therapy, Combination

KW - Anti-Bacterial Agents/therapeutic use

KW - Aza Compounds/therapeutic use

KW - Multiple Organ Failure/etiology/prevention & control

KW - Quinolines/therapeutic use

KW - Sepsis/complications/drug therapy

KW - Shock, Septic/complications/drug therapy

KW - Thienamycins/therapeutic use

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Survival Analysis

KW - Drug Therapy, Combination

KW - Anti-Bacterial Agents/therapeutic use

KW - Aza Compounds/therapeutic use

KW - Multiple Organ Failure/etiology/prevention & control

KW - Quinolines/therapeutic use

KW - Sepsis/complications/drug therapy

KW - Shock, Septic/complications/drug therapy

KW - Thienamycins/therapeutic use

M3 - SCORING: Journal article

VL - 307

SP - 2390

EP - 2399

JO - JAMA-J AM MED ASSOC

JF - JAMA-J AM MED ASSOC

SN - 0098-7484

IS - 22

M1 - 22

ER -